Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Katagishi, Daiki, Yasuda, Daisuke, Takahashi, Kyoko, Nakamura, Shigeo, Mashino, Tadahiko, Ohe, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798672/
https://www.ncbi.nlm.nih.gov/pubmed/36587873
http://dx.doi.org/10.1016/j.bmcl.2022.129121
Descripción
Sumario:COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.

Ejemplares similares